STOCK TITAN

SS Innovations International (SSII) SEC Filings

SSII NASDAQ

SS Innovations International Inc. filings document a Nasdaq-listed surgical robotics issuer and its formal disclosures around the SSi Mantra platform. Recent Current Reports on Form 8-K record product and regulatory updates, telesurgery announcements, conference-related disclosures, financial-results releases and Regulation FD communications.

The filing record also covers capital structure events, including an unregistered private placement of common stock, and identifies the company’s common stock as registered on Nasdaq under SSII. Annual-report and current-report disclosures provide formal context for operating results, product development, clinical and regulatory timelines, forward-looking statements, and the company’s subsidiary-based reporting perimeter.

Rhea-AI Summary

SS Innovations International, Inc. (SSII) announced the world’s first dual-console, beating-heart TECAB surgery using all five arms of its SSi Mantra system, performed by surgeons at Medanta - The Medicity Hospital in Gurugram, India. The Totally Endoscopic Coronary Artery Bypass was conducted while the heart continued beating, without opening the chest or using a heart-lung machine.

Medanta Chairman and Managing Director Dr. Naresh Trehan said the patient was doing extremely well. SSII says the SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

SS Innovations International, Inc. (SSII) reported a purchase of 100,000 shares held of record by Sushruta Pvt. Ltd., in which Chairman and CEO Sudhir Srivastava has a controlling interest. The purchase was made on November 17, 2026, at $3.00 per share. Its price was paid by satisfying $300,000 in accrued but unpaid compensation SSII owed Srivastava. After the transaction, 108,550,928 shares were reported held indirectly through Sushruta Pvt. Ltd. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

SS Innovations International, Inc. reported that Chairman and Chief Executive Officer Dr. Sudhir Srivastava, through his holding company Sushruta Pvt. Ltd., purchased 100,000 shares of the company’s common stock on November 17, 2026, at $3.00 per share, for an aggregate purchase price of $300,000. The purchase price was paid through an exchange involving $300,000 in accrued but unpaid compensation owed by the company to Dr. Srivastava. The shares were offered and sold under the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

SS Innovations International, Inc. (SSII) reported that CFO Gary Garlai Lo held directly options to purchase 500,000 common shares, granted November 6, 2026. The options have an exercise price of $2.11 per share and vest in four annual installments beginning on the first anniversary, subject to continued employment and the 2026 Incentive Stock Plan’s terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

SS Innovations International, Inc. (SSII) reported nine-month revenue of $31.4 million, compared with $28.0 million in 2025, while its net loss was $12.0 million versus $9.7 million. For the third quarter, revenue was $6.3 million compared with $12.8 million, and net loss was $5.7 million versus $3.7 million. Net cash used in operating activities for the nine months was $12.9 million, compared with $17.0 million.

On October 9, 2026, SSII received $20.0 million in gross proceeds from investor Growth Capital Partners, LLC, issuing a secured convertible promissory note with $21.025 million principal. The note bears 8.75% annual interest, matures 36 months after issuance, converts at 95% of the defined Market Price, and is subject to monthly investor redemptions beginning 12 months after issuance, payable in cash or shares. It is secured by SSII’s intellectual property and assets and those of SSI IP Holdings, excluding SSI-India’s assets and capital stock. SSII intends to use net proceeds for working capital and general corporate purposes. The company said existing cash resources and operating income are not expected to fund operations and business development through the next 12 months, and that these conditions raise substantial doubt about its ability to continue as a going concern.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
quarterly report
-
Rhea-AI Summary

SS Innovations International, Inc. (SSII) reported that Sushruta Pvt. Ltd., in which its Chairman and CEO Sudhir Srivastava has a controlling interest, transferred 20,000 shares of its common stock as a bona fide gift on November 10, 2026. Sushruta Pvt. Ltd. held 108,450,928 shares after the transfer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.67%
Tags
insider
Rhea-AI Summary

SS Innovations International, Inc. (SSII) appointed Gary G. Lo as Chief Financial Officer and Dr. Vishwajyoti P. Srivastava, previously Chief Executive Officer – Asia Pacific, as President, effective November 6, 2026. Lo’s agreement provides for $400,000 in annual base compensation, a target annual cash bonus of 50% of base salary subject to performance criteria, and options for 500,000 shares at an exercise price of $2.11 per share. The options vest in four annual installments beginning on the first anniversary, subject to continued employment, and expire ten years after the effective date. If terminated without Cause, subject to a release, Lo is eligible for three months of base salary in severance before the first anniversary or six months on or after it.

Srivastava’s base salary increased to $500,000 in connection with his appointment and relocation to the United States. He will oversee efforts to obtain U.S. and European Union marketing approvals for the SSi Mantra robotic surgical system and prepare for entry into those markets after approval. The company disclosed that it is responding to FDA queries during review of its 510(k) premarket notification and continuing toward CE marking in the EU. Srivastava is the son of Chairman and Chief Executive Officer Dr. Sudhir Srivastava; the company said it is negotiating other terms of a new employment agreement with him.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.76%
Tags
current report
-
Rhea-AI Summary

SS Innovations International, Inc. (SSII) said its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console were showcased in successful telesurgeries in October 2026 at the EACTS Annual Meeting in Barcelona and the Society of Robotic Surgery India Conference in New Delhi. At EACTS, Chairman and CEO Dr. Sudhir Srivastava performed a robotic atrial septal defect procedure from Barcelona, approximately 7,500 miles (12,000 kilometers) from the patient in Bengaluru; Dr. Lalit Malik, Chief Cardiac Surgeon of Manipal Hospital Jaipur, provided patient-side support.

At SRS India, four surgeons completed four separate telesurgeries: a right partial nephrectomy, right hemicolectomy, left-sided pyeloplasty on a pediatric patient, and modified radical hysterectomy with sentinel lymph node biopsy. SS Innovations said 205 telesurgeries, including intricate cardiac procedures, had been performed with the SSi Mantra as of October 23, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
current report
-
Rhea-AI Summary

SS Innovations International, Inc. (SSII) submitted its response to a U.S. Food and Drug Administration request for additional information regarding the SSi Mantra surgical robotic system’s 510(k) submission on October 5, 2026. The response includes final data from an expanded human clinical and human factors validation study, along with final data from a bridging study completed in August 2026 at Hospital Internacional de Colombia in Bucaramanga, Colombia.

SS Innovations anticipates that the FDA will complete its review of the response and 510(k) submission in the first quarter of 2027. The submission covers an initial indication of cholecystectomy, or gallbladder removal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
current report
Rhea-AI Summary

SS Innovations International, Inc. (SSII) issued a secured convertible promissory note with an original principal of $21,025,000 for a purchase price of $20,000,000 on October 9, 2026. The $1,025,000 difference comprises a $1,000,000 original issue discount and $25,000 in transaction expenses. The note bears 8.75% interest per annum, compounded daily, and matures 36 months after closing. An initial reserve of 8,000,000 Common Shares was established for conversions, with 100,000-share increases as required by the purchase agreement.

From the effective date, the investor may convert outstanding amounts at 95% of Market Price if the trading price is at least 10% higher. Beginning on the 12-month anniversary, the investor may redeem all or part, subject to a monthly cap equal to the note balance on that anniversary divided by 24. The company may pay redemptions in cash, Common Shares, or both, and may prepay with five trading days’ prior written notice, except for amounts under conversion notices whose shares remain undelivered. Collateral includes company and SS IP assets, including intellectual property, but excludes SSI-India’s assets and capital stock; subsidiaries other than SSI-India guarantee the note. Conversions are subject to a 4.99% beneficial-ownership cap, increasable to 9.99% on 61 days’ notice, and the Nasdaq Exchange Cap unless shareholder approval is obtained or it is otherwise inapplicable.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
current report

FAQ

How many SS Innovations International (SSII) SEC filings are available on StockTitan?

StockTitan tracks 93 SEC filings for SS Innovations International (SSII), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for SS Innovations International (SSII)?

The most recent SEC filing for SS Innovations International (SSII) was filed on November 19, 2026.